Armata pharmaceuticals inc
ARMP 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
ARMP 近期報酬表現
14.77%
Armata pharmaceuticals inc
1.66%
同產業平均
-0.54%
S&P500
與 ARMP 同產業的標的表現
| 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 市值 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
UPC Universe pharmaceuticals inc | - | 3 分 | 3 分 | - | 1 分 | 4.1M | |
MNK Mallinckrodt plc | - | - | - | - | 1 分 | 4.5M | |
URGN Urogen pharma ltd | 4 分 | 4 分 | 3 分 | 3 分 | 1 分 | 402.2M | |
GLTO Galecto inc | 2 分 | 1 分 | 3 分 | 1 分 | 1 分 | 16.3M | |
ACHV Achieve life sciences inc | 4 分 | 5 分 | 2 分 | 1 分 | 1 分 | 121.9M |
- UPC Universe pharmaceuticals inc價值 -趨勢 3 分波段 3 分籌碼 -股利 1 分市值 4.1M查看更多
ARMP 公司資訊
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.